Vitamin K antagonist has a higher impact than heparin in preventing circuit clotting in chronic haemodialysis patients

BackgroundIn dialysis sessions, some data suggest that decreasing or even avoiding additional anticoagulation by heparin is possible among patients already treated with oral anticoagulation. However, the required dose of heparin may actually depend on the pre-dialysis international normalized ratio...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Kidney Journal 2020-08, Vol.13 (4), p.647-653
Main Authors: Charles, Pierre-Yves, Le Meur, Yannick, Tanquerel, Tugdual, Galinat, Hubert
Format: Article
Language:English
Subjects:
Blood clotting
Health aspects
Hemodialysis patients
Immunology
Life Sciences
Original
Physiological aspects
Prevention
Vitamin K
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c509t-69c8020bcf718a3df0dd54dfcb17220b4533d1af4c3deef4fb39fcf6580192f33
cites
container_end_page 653
container_issue 4
container_start_page 647
container_title Clinical Kidney Journal
container_volume 13
creator Charles, Pierre-Yves
Le Meur, Yannick
Tanquerel, Tugdual
Galinat, Hubert
description BackgroundIn dialysis sessions, some data suggest that decreasing or even avoiding additional anticoagulation by heparin is possible among patients already treated with oral anticoagulation. However, the required dose of heparin may actually depend on the pre-dialysis international normalized ratio (INR), which varies from one session to another. The aim of our study was to determine the respective role of INR and heparin dosing in the risk of circuit clotting during chronic haemodialysis.Methods From early 2012 to July 2016, we analysed the totality of dialysis sessions performed at Brest University Hospital among haemodialysis patients treated by vitamin K antagonists (VKA). We established a prediction of circuit clotting on the basis of a simplified score obtained by combining INR and heparin dosing.ResultsIn total, 7184 dialysis sessions among chronic haemodialysis patients under VKA were identified, including 233 with clotting events. The mean INR without clotting events was 2.5 versus 1.8 with clotting events (P 
doi_str_mv 10.1093/ckj/sfz131
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7467595</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A645072356</galeid><oup_id>10.1093/ckj/sfz131</oup_id><sourcerecordid>A645072356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-69c8020bcf718a3df0dd54dfcb17220b4533d1af4c3deef4fb39fcf6580192f33</originalsourceid><addsrcrecordid>eNptkl1rHCEUhqW0NCHJTX9AEUqhudhER52Pm8ISmqZkITdpb8V1dMZ0RqfqLKS_vmc76dKUqqCc9znvUTwIvaHkgpKGXervD5fJ_qSMvkDHBeH1qhaUvTyciThCZyk9EBigEC5eoyNWNEQw1hyj3TeX1eg8vsXKZ9UF71LGvUpY4d51vYnYjZPSGedeedybSUWgYU3R7IzPzndYu6hnl7EeQv4dAFn3Ebw0WJkxtE4Nj8klPKnsICmdoldWDcmcPe0n6Ov1p_urm9Xm7vOXq_VmpQVp8qpsdE0KstW2orVirSVtK3hr9ZZWBcQ5PKKlynLNWmMst1vWWG1LURPaFJaxE_Rx8Z3m7WhaDbWjGuQU3ajiowzKyeeKd73swk5WvKxEI8DgfDHo_0m7WW_kPkYKRsuG8h0F9sNTsRh-zCZlObqkzTAob8KcZME5LSmtqgrQdwvaqcFI522A6nqPy3XJBakKJkqgLv5DwWzN6HTwxjqIP0t4-_dzDxf-898AvF-AME8HlRK5byUJrSSXVmK_AEdTu0U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2441611777</pqid></control><display><type>article</type><title>Vitamin K antagonist has a higher impact than heparin in preventing circuit clotting in chronic haemodialysis patients</title><source>PubMed Central</source><source>Oxford Academic Journals (Open Access)</source><creator>Charles, Pierre-Yves ; Le Meur, Yannick ; Tanquerel, Tugdual ; Galinat, Hubert</creator><creatorcontrib>Charles, Pierre-Yves ; Le Meur, Yannick ; Tanquerel, Tugdual ; Galinat, Hubert</creatorcontrib><description>BackgroundIn dialysis sessions, some data suggest that decreasing or even avoiding additional anticoagulation by heparin is possible among patients already treated with oral anticoagulation. However, the required dose of heparin may actually depend on the pre-dialysis international normalized ratio (INR), which varies from one session to another. The aim of our study was to determine the respective role of INR and heparin dosing in the risk of circuit clotting during chronic haemodialysis.Methods From early 2012 to July 2016, we analysed the totality of dialysis sessions performed at Brest University Hospital among haemodialysis patients treated by vitamin K antagonists (VKA). We established a prediction of circuit clotting on the basis of a simplified score obtained by combining INR and heparin dosing.ResultsIn total, 7184 dialysis sessions among chronic haemodialysis patients under VKA were identified, including 233 with clotting events. The mean INR without clotting events was 2.5 versus 1.8 with clotting events (P &lt; 0.001). Frequencies of circuit clotting were different according to INR group (INR &lt;2.0, INR 2.0–3.0, INR &gt;3.0; P &lt; 0.0001). The protective role of VKA was higher than heparin, as shown by discriminant factor analysis (P &lt; 0.0001). Conclusion. Our study established a predictive model of thrombosis risk of dialysis circuits in patients treated by VKA for a given heparin dose and a given INR. This model shows a marginal contribution of heparin to protect against the risk of thrombosis compared with VKA. Moreover, heparin would not appear to be necessary for patients with an INR &gt;2.2.</description><identifier>ISSN: 2048-8505</identifier><identifier>EISSN: 2048-8513</identifier><identifier>DOI: 10.1093/ckj/sfz131</identifier><identifier>PMID: 32905339</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Blood clotting ; Health aspects ; Hemodialysis patients ; Immunology ; Life Sciences ; Original ; Physiological aspects ; Prevention ; Vitamin K</subject><ispartof>Clinical Kidney Journal, 2020-08, Vol.13 (4), p.647-653</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.</rights><rights>COPYRIGHT 2020 Oxford University Press</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-69c8020bcf718a3df0dd54dfcb17220b4533d1af4c3deef4fb39fcf6580192f33</citedby><orcidid>0000-0001-8913-415X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467595/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467595/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32905339$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02316914$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Charles, Pierre-Yves</creatorcontrib><creatorcontrib>Le Meur, Yannick</creatorcontrib><creatorcontrib>Tanquerel, Tugdual</creatorcontrib><creatorcontrib>Galinat, Hubert</creatorcontrib><title>Vitamin K antagonist has a higher impact than heparin in preventing circuit clotting in chronic haemodialysis patients</title><title>Clinical Kidney Journal</title><addtitle>Clin Kidney J</addtitle><description>BackgroundIn dialysis sessions, some data suggest that decreasing or even avoiding additional anticoagulation by heparin is possible among patients already treated with oral anticoagulation. However, the required dose of heparin may actually depend on the pre-dialysis international normalized ratio (INR), which varies from one session to another. The aim of our study was to determine the respective role of INR and heparin dosing in the risk of circuit clotting during chronic haemodialysis.Methods From early 2012 to July 2016, we analysed the totality of dialysis sessions performed at Brest University Hospital among haemodialysis patients treated by vitamin K antagonists (VKA). We established a prediction of circuit clotting on the basis of a simplified score obtained by combining INR and heparin dosing.ResultsIn total, 7184 dialysis sessions among chronic haemodialysis patients under VKA were identified, including 233 with clotting events. The mean INR without clotting events was 2.5 versus 1.8 with clotting events (P &lt; 0.001). Frequencies of circuit clotting were different according to INR group (INR &lt;2.0, INR 2.0–3.0, INR &gt;3.0; P &lt; 0.0001). The protective role of VKA was higher than heparin, as shown by discriminant factor analysis (P &lt; 0.0001). Conclusion. Our study established a predictive model of thrombosis risk of dialysis circuits in patients treated by VKA for a given heparin dose and a given INR. This model shows a marginal contribution of heparin to protect against the risk of thrombosis compared with VKA. Moreover, heparin would not appear to be necessary for patients with an INR &gt;2.2.</description><subject>Blood clotting</subject><subject>Health aspects</subject><subject>Hemodialysis patients</subject><subject>Immunology</subject><subject>Life Sciences</subject><subject>Original</subject><subject>Physiological aspects</subject><subject>Prevention</subject><subject>Vitamin K</subject><issn>2048-8505</issn><issn>2048-8513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNptkl1rHCEUhqW0NCHJTX9AEUqhudhER52Pm8ISmqZkITdpb8V1dMZ0RqfqLKS_vmc76dKUqqCc9znvUTwIvaHkgpKGXervD5fJ_qSMvkDHBeH1qhaUvTyciThCZyk9EBigEC5eoyNWNEQw1hyj3TeX1eg8vsXKZ9UF71LGvUpY4d51vYnYjZPSGedeedybSUWgYU3R7IzPzndYu6hnl7EeQv4dAFn3Ebw0WJkxtE4Nj8klPKnsICmdoldWDcmcPe0n6Ov1p_urm9Xm7vOXq_VmpQVp8qpsdE0KstW2orVirSVtK3hr9ZZWBcQ5PKKlynLNWmMst1vWWG1LURPaFJaxE_Rx8Z3m7WhaDbWjGuQU3ajiowzKyeeKd73swk5WvKxEI8DgfDHo_0m7WW_kPkYKRsuG8h0F9sNTsRh-zCZlObqkzTAob8KcZME5LSmtqgrQdwvaqcFI522A6nqPy3XJBakKJkqgLv5DwWzN6HTwxjqIP0t4-_dzDxf-898AvF-AME8HlRK5byUJrSSXVmK_AEdTu0U</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Charles, Pierre-Yves</creator><creator>Le Meur, Yannick</creator><creator>Tanquerel, Tugdual</creator><creator>Galinat, Hubert</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8913-415X</orcidid></search><sort><creationdate>20200801</creationdate><title>Vitamin K antagonist has a higher impact than heparin in preventing circuit clotting in chronic haemodialysis patients</title><author>Charles, Pierre-Yves ; Le Meur, Yannick ; Tanquerel, Tugdual ; Galinat, Hubert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-69c8020bcf718a3df0dd54dfcb17220b4533d1af4c3deef4fb39fcf6580192f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Blood clotting</topic><topic>Health aspects</topic><topic>Hemodialysis patients</topic><topic>Immunology</topic><topic>Life Sciences</topic><topic>Original</topic><topic>Physiological aspects</topic><topic>Prevention</topic><topic>Vitamin K</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Charles, Pierre-Yves</creatorcontrib><creatorcontrib>Le Meur, Yannick</creatorcontrib><creatorcontrib>Tanquerel, Tugdual</creatorcontrib><creatorcontrib>Galinat, Hubert</creatorcontrib><collection>Oxford Academic Journals (Open Access)</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical Kidney Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Charles, Pierre-Yves</au><au>Le Meur, Yannick</au><au>Tanquerel, Tugdual</au><au>Galinat, Hubert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin K antagonist has a higher impact than heparin in preventing circuit clotting in chronic haemodialysis patients</atitle><jtitle>Clinical Kidney Journal</jtitle><addtitle>Clin Kidney J</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>13</volume><issue>4</issue><spage>647</spage><epage>653</epage><pages>647-653</pages><issn>2048-8505</issn><eissn>2048-8513</eissn><abstract>BackgroundIn dialysis sessions, some data suggest that decreasing or even avoiding additional anticoagulation by heparin is possible among patients already treated with oral anticoagulation. However, the required dose of heparin may actually depend on the pre-dialysis international normalized ratio (INR), which varies from one session to another. The aim of our study was to determine the respective role of INR and heparin dosing in the risk of circuit clotting during chronic haemodialysis.Methods From early 2012 to July 2016, we analysed the totality of dialysis sessions performed at Brest University Hospital among haemodialysis patients treated by vitamin K antagonists (VKA). We established a prediction of circuit clotting on the basis of a simplified score obtained by combining INR and heparin dosing.ResultsIn total, 7184 dialysis sessions among chronic haemodialysis patients under VKA were identified, including 233 with clotting events. The mean INR without clotting events was 2.5 versus 1.8 with clotting events (P &lt; 0.001). Frequencies of circuit clotting were different according to INR group (INR &lt;2.0, INR 2.0–3.0, INR &gt;3.0; P &lt; 0.0001). The protective role of VKA was higher than heparin, as shown by discriminant factor analysis (P &lt; 0.0001). Conclusion. Our study established a predictive model of thrombosis risk of dialysis circuits in patients treated by VKA for a given heparin dose and a given INR. This model shows a marginal contribution of heparin to protect against the risk of thrombosis compared with VKA. Moreover, heparin would not appear to be necessary for patients with an INR &gt;2.2.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>32905339</pmid><doi>10.1093/ckj/sfz131</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-8913-415X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2048-8505
ispartof Clinical Kidney Journal, 2020-08, Vol.13 (4), p.647-653
issn 2048-8505
2048-8513
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7467595
source PubMed Central; Oxford Academic Journals (Open Access)
subjects Blood clotting
Health aspects
Hemodialysis patients
Immunology
Life Sciences
Original
Physiological aspects
Prevention
Vitamin K
title Vitamin K antagonist has a higher impact than heparin in preventing circuit clotting in chronic haemodialysis patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T21%3A52%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20K%20antagonist%20has%20a%20higher%20impact%20than%20heparin%20in%20preventing%20circuit%20clotting%20in%20chronic%20haemodialysis%20patients&rft.jtitle=Clinical%20Kidney%20Journal&rft.au=Charles,%20Pierre-Yves&rft.date=2020-08-01&rft.volume=13&rft.issue=4&rft.spage=647&rft.epage=653&rft.pages=647-653&rft.issn=2048-8505&rft.eissn=2048-8513&rft_id=info:doi/10.1093/ckj/sfz131&rft_dat=%3Cgale_pubme%3EA645072356%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c509t-69c8020bcf718a3df0dd54dfcb17220b4533d1af4c3deef4fb39fcf6580192f33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2441611777&rft_id=info:pmid/32905339&rft_galeid=A645072356&rft_oup_id=10.1093/ckj/sfz131&rfr_iscdi=true